is an innate inhibitor that effectively targeted NLRP3, suppressing activation of NLRP3 inflammasome in an NF-κB-independent manner and inhibiting assembly of the NLRP3 inflammasome by directly binding to the NACHT domain of NLRP3 (169), which suggests that Britannin may be an effective drug inhibiting macrophages to reduce ALI/ARDS. The gene discussed is NLRP3; the disease is acute respiratory distress syndrome.